Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page
- Check7 days agoChange DetectedRevision updated from v3.5.2 to v3.5.3, indicating a minor update to the page's revision history for this study record on ClinicalTrials.gov.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check50 days agoChange DetectedRevision metadata updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing the prior v3.4.2.SummaryDifference0.1%

- Check86 days agoChange DetectedRevision: v3.4.2 added. The previous notice about a lapse in government funding and related operating status information (Revision: v3.4.1) was removed.SummaryDifference0.4%

- Check93 days agoChange DetectedA site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status was added. The revision tag changed from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.